Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - DENDREON CORPexhibit_99-1.htm


SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
 
FORM 8-K
________________
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 26, 2011
________________
 
DENDREON CORPORATION
(Exact name of registrant as specified in its charter)
________________
 
Delaware
000-30681
22-3203193
(State or other jurisdiction
(Commission File Number)
(I.R.S. Employer
of incorporation)
 
Identification Number)

 
1301 2nd Avenue, Suite 3200
Seattle, WA  98101
(Address of principal executive offices) (zip code)
 
(206) 256-4545
(Registrant’s telephone number, including area code)
 
3005 First Avenue
Seattle, WA  98121
(Former name or former address, if changed since last report)
________________
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

£           Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

£           Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

£           Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

£           Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 


 
 

 
 
Item 8.01. Other Events.
 
    On August 26, 2011, Dendreon Corporation (the “Company”) announced that the U.S. Food and Drug Administration approved its immunotherapy manufacturing facility in Union City, Georgia for the commercial manufacture of PROVENGE® (sipuleucel-T), allowing the Company to increase the nationwide availability of PROVENGE to help meet the needs of patients across the U.S. with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. See attached Exhibit 99.1 for the full text of the press release.
 
 
Item 9.01. Financial Statements and Exhibits.
 
    (d) Exhibits
 
99.1  Dendreon Corporation press release dated August 26, 2011.
 
 
2

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  DENDREON CORPORATION  
       
 
By:
/s/ Gregory T. Schiffman  
    Gregory T. Schiffman  
    Executive Vice President, Chief Financial Officer and Treasurer  
Date:  August 29, 2011      

3